Abstract
Hepatitis B virus (HBV) is a DNA virus, belonging to the Hepadnaviridae family. It is a partially double-stranded DNA virus with a small viral genome (3.2 kb). Chronic HBV infection remains a global public health problem. If left untreated, chronic HBV infection can progress to end-stage liver disease, such as liver cirrhosis and hepatocellular carcinoma (HCC). In recent years, tremendous advances in the field of HBV basic and clinical research have been achieved, ranging from the HBV biological characteristics, immunopathogenesis, and animal models to the development of new therapeutic strategies and new drugs against HBV. In this overview, we begin with a brief history of HBV discovery and treatment milestones. We then briefly summarize the HBV research advances, which will be detailed in the following chapters.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Maccallum FO (1946) Homologous serum hepatitis. Proc R Soc Med 39(10):655–657
Blumberg BS (1964) Polymorphisms of the serum proteins and the development of Iso-precipitins in transfused patients. Bull N Y Acad Med 40:377–386
Blumberg BS, Alter HJ, Visnich S (1965) A “New” antigen in leukemia sera. JAMA 191:541–546
Blumberg BS, Gerstley BJ, Hungerford DA, London WT, Sutnick AI (1967) A serum antigen (Australia antigen) in Down’s syndrome, leukemia, and hepatitis. Ann Intern Med 66(5):924–931
Bayer ME, Blumberg BS, Werner B (1968) Particles associated with Australia antigen in the sera of patients with leukaemia, down’s syndrome and hepatitis. Nature 218(5146):1057–1059
Prince AM, Fuji H, Gershon RK (1964) Immunohistochemical studies on the etiology of anicteric hepatitis in Korea. Am J Hyg 79:365–381
Prince AM (1968) An antigen detected in the blood during the incubation period of serum hepatitis. Proc Natl Acad Sci U S A 60(3):814–821
Prince AM (1968) Relation of Australia and SH antigens. Lancet 2(7565):462–463
Dane DS, Cameron CH, Briggs M (1970) Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1(7649):695–698
Galibert F, Mandart E, Fitoussi F, Tiollais P, Charnay P (1979) Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature 281(5733):646–650
Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC et al (1980) Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 303(15):833–841
Valenzuela P, Gray P, Quiroga M, Zaldivar J, Goodman HM, Rutter WJ (1979) Nucleotide sequence of the gene coding for the major protein of hepatitis B virus surface antigen. Nature 280(5725):815–819
Edman JC, Hallewell RA, Valenzuela P, Goodman HM, Rutter WJ (1981) Synthesis of hepatitis B surface and core antigens in E. coli. Nature 291(5815):503–506
Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD (1982) Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 298(5872):347–350
McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR (1984) Human hepatitis B vaccine from recombinant yeast. Nature 307(5947):178–180
Brunetto MR (2010) A new role for an old marker, HBsAg. J Hepatol 52(4):475–477
Sonneveld MJ, Zoutendijk R, Janssen HL (2011) Hepatitis B surface antigen monitoring and management of chronic hepatitis B. J Viral Hepat 18(7):449–457
Trepo C (2014) A brief history of hepatitis milestones. Liver Int 34(Suppl 1):29–37
Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z et al (1999) Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341(17):1256–1263
WHO (2017) Global hepatitis report, 2017. [updated April 2017; cited 2019 June 11]
Liang X, Bi S, Yang W, Wang L, Cui G, Cui F et al (2009) Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. Vaccine 27(47):6550–6557
Liang X, Bi S, Yang W, Wang L, Cui G, Cui F et al (2009) Evaluation of the impact of hepatitis B vaccination among children born during 1992–2005 in China. J Infect Dis 200(1):39–47
Lu FM, Zhuang H (2009) Management of hepatitis B in China. Chin Med J 122(1):3–4
Polaris Observatory C (2018) Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol 3(6):383–403
Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH et al (2016) AASLD guidelines for treatment of chronic hepatitis B. Hepatology (Baltimore, MD) 63(1):261–283
Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM et al (2018) Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology (Baltimore, MD) 67(4):1560–1599
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 (2017) Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 67(2):370–398
Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM et al (2002) Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology (Baltimore, MD) 35(6):1522–1527
Fattovich G, Bortolotti F, Donato F (2008) Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 48(2):335–352
Chu CM, Liaw YF (2006) Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 26(2):142–152
Chen YC, Chu CM, Yeh CT, Liaw YF (2007) Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int 1(1):267–273
WHO (2018) The top 10 causes of death. [updated May 24 2018; cited 2019 June 11]
Sureau C, Salisse J (2013) A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant. Hepatology (Baltimore, MD) 57(3):985–994
Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z et al (2012) Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. elife 1:e00049
Hayes CN, Zhang Y, Makokha GN, Hasan MZ, Omokoko MD, Chayama K (2016) Early events in hepatitis B virus infection: from the cell surface to the nucleus. J Gastroenterol Hepatol 31(2):302–309
Nassal M (2015) HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut 64(12):1972–1984
Jones SA, Hu J (2013) Protein-primed terminal transferase activity of hepatitis B virus polymerase. J Virol 87(5):2563–2576
Nassal M (2008) Hepatitis B viruses: reverse transcription a different way. Virus Res 134(1–2):235–249
Hu J, Liu K (2017) Complete and incomplete hepatitis B virus particles: formation, function, and application. Viruses 9(3):56
Tang H, Banks KE, Anderson AL, McLachlan A (2001) Hepatitis B virus transcription and replication. Drug News Perspect 14(6):325–334
Tang H, McLachlan A (2001) Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism. Proc Natl Acad Sci U S A 98(4):1841–1846
Reese V, Ondracek C, Rushing C, Li L, Oropeza CE, McLachlan A (2011) Multiple nuclear receptors may regulate hepatitis B virus biosynthesis during development. Int J Biochem Cell Biol 43(2):230–237
Shalaby RE, Iram S, Cakal B, Oropeza CE, McLachlan A (2017) PGC1 alpha transcriptional adaptor function governs hepatitis B virus replication by controlling HBcAg/p21 protein-mediated capsid formation. J Virol 91(20)
Shalaby RE, Iram S, Oropeza CE, McLachlan A (2019) Peroxisome proliferator-activated receptor gamma coactivator family members competitively regulate hepatitis b virus biosynthesis. Virology 526:214–221
Reese VC, Moore DD, McLachlan A (2012) Limited effects of bile acids and small heterodimer partner on hepatitis B virus biosynthesis in vivo. J Virol 86(5):2760–2768
Chen Y, Hu J, Cai X, Huang Y, Zhou X, Tu Z et al (2018) APOBEC3B edits HBV DNA and inhibits HBV replication during reverse transcription. Antivir Res 149:16–25
Xie N, Yuan K, Zhou L, Wang K, Chen HN, Lei Y et al (2016) PRKAA/AMPK restricts HBV replication through promotion of autophagic degradation. Autophagy 12(9):1507–1520
Zhang W, Chen J, Wu M, Zhang X, Zhang M, Yue L et al (2017) PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation. Hepatology (Baltimore, MD) 66(2):398–415
Gong DY, Chen EQ, Huang FJ, Leng XH, Cheng X, Tang H (2013) Role and functional domain of hepatitis B virus X protein in regulating HBV transcription and replication in vitro and in vivo. Viruses 5(5):1261–1271
Tang H, Delgermaa L, Huang F, Oishi N, Liu L, He F et al (2005) The transcriptional transactivation function of HBx protein is important for its augmentation role in hepatitis B virus replication. J Virol 79(9):5548–5556
Bouchard MJ, Wang L, Schneider RJ (2006) Activation of focal adhesion kinase by hepatitis B virus HBx protein: multiple functions in viral replication. J Virol 80(9):4406–4414
Decorsiere A, Mueller H, van Breugel PC, Abdul F, Gerossier L, Beran RK et al (2016) Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor. Nature 531(7594):386–389
Murphy CM, Xu Y, Li F, Nio K, Reszka-Blanco N, Li X et al (2016) Hepatitis B virus X protein promotes degradation of SMC5/6 to enhance HBV replication. Cell Rep 16(11):2846–2854
Guidotti LG, Chisari FV (2001) Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 19:65–91
Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R et al (2009) Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology (Baltimore, MD) 49(4):1132–1140
Chen J, Wu M, Zhang X, Zhang W, Zhang Z, Chen L et al (2013) Hepatitis B virus polymerase impairs interferon-alpha-induced STA T activation through inhibition of importin-alpha5 and protein kinase C-delta. Hepatology (Baltimore, MD) 57(2):470–482
Wei C, Ni C, Song T, Liu Y, Yang X, Zheng Z et al (2010) The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J Immunol (Baltimore, MD: 1950) 185(2):1158–1168
Jiang J, Tang H (2010) Mechanism of inhibiting type I interferon induction by hepatitis B virus X protein. Protein Cell 1(12):1106–1117
Han Q, Zhang C, Zhang J, Tian Z (2011) Reversal of hepatitis B virus-induced immune tolerance by an immunostimulatory 3p-HBx-siRNAs in a retinoic acid inducible gene I-dependent manner. Hepatology (Baltimore, MD) 54(4):1179–1189
Bertoletti A, Ferrari C (2012) Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 61(12):1754–1764
Isogawa M, Tanaka Y (2015) Immunobiology of hepatitis B virus infection. Hepatol Res 45(2):179–189
Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM et al (2007) Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 46(1):45–52
Wong DK, Cheung AM, O’Rourke K, Naylor CD, Detsky AS, Heathcote J (1993) Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 119(4):312–323
Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G et al (2005) Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352(26):2682–2695
Piratvisuth T, Lau G, Chao YC, Jin R, Chutaputti A, Zhang QB et al (2008) Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int 2(1):102–110
Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y et al (2005) Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365(9454):123–129
Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C et al (2003) Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36(6):687–696
Han GR, Cao MK, Zhao W, Jiang HX, Wang CM, Bai SF et al (2011) A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 55(6):1215–1221
Han GR, Jiang HX, Yue X, Ding Y, Wang CM, Wang GJ et al (2015) Efficacy and safety of telbivudine treatment: an open-label, prospective study in pregnant women for the prevention of perinatal transmission of hepatitis B virus infection. J Viral Hepat 22(9):754–762
Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Arterburn S et al (2008) Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology (Baltimore, MD) 48(3):750–758
Seto WK, Lai CL, Fung J, Wong DK, Yuen JC, Hung IF et al (2011) Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. J Hepatol 55(3):522–528
Yokosuka O, Takaguchi K, Fujioka S, Shindo M, Chayama K, Kobashi H et al (2010) Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection. J Hepatol 52(6):791–799
Kitrinos KM, Corsa A, Liu Y, Flaherty J, Snow-Lampart A, Marcellin P et al (2014) No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology (Baltimore, MD) 59(2):434–442
Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R et al (2004) Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351(12):1206–1217
Stelma F, van der Ree MH, Jansen L, Peters MW, Janssen HLA, Zaaijer HL et al (2017) HBsAg loss after peginterferon-nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up. J Viral Hepat 24(12):1107–1113
Marcellin P, Ahn SH, Ma X, Caruntu FA, Tak WY, Elkashab M et al (2016) Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology 150(1):134–144. e10
de Niet A, Jansen L, Stelma F, Willemse SB, Kuiken SD, Weijer S et al (2017) Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial. Lancet Gastroenterol Hepatol 2(8):576–584
Marcellin P, Ahn SH, Chuang WL, Hui AJ, Tabak F, Mehta R et al (2016) Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B. Aliment Pharmacol Ther 44(9):957–966
Brouwer WP, Xie Q, Sonneveld MJ, Zhang N, Zhang Q, Tabak F et al (2015) Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: a multicenter randomized trial (ARES study). Hepatology (Baltimore, MD) 61(5):1512–1522
van Campenhout MJH, Brouwer WP, Xie Q, Guo S, Chi H, Qi X et al (2019) Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBeAg-positive chronic hepatitis B infection: ARES long-term follow-up. J Viral Hepat 26(1):109–117
Bourliere M, Rabiega P, Ganne-Carrie N, Serfaty L, Marcellin P, Barthe Y et al (2017) Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. Lancet Gastroenterol Hepatol 2(3):177–188
Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J et al (2014) Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol 61(4):777–784
Hu P, Shang J, Zhang W, Gong G, Li Y, Chen X et al (2018) HBsAg loss with peg-interferon Alfa-2a in hepatitis B patients with partial response to Nucleos(t)ide analog: new switch study. J Clin Transl Hepatol 6(1):25–34
Blank A, Markert C, Hohmann N, Carls A, Mikus G, Lehr T et al (2016) First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol 65(3):483–489
Blank A, Eidam A, Haag M, Hohmann N, Burhenne J, Schwab M et al (2018) The NTCP-inhibitor Myrcludex B: effects on bile acid disposition and Tenofovir pharmacokinetics. Clin Pharmacol Ther 103(2):341–348
Gaj T, Gersbach CA, Barbas CF 3rd. (2013) ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 31(7):397–405
Sander JD, Joung JK (2014) CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 32(4):347–355
Schiffer JT, Aubert M, Weber ND, Mintzer E, Stone D, Jerome KR (2012) Targeted DNA mutagenesis for the cure of chronic viral infections. J Virol 86(17):8920–8936
Dong C, Qu L, Wang H, Wei L, Dong Y, Xiong S (2015) Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. Antivir Res 118:110–117
Kennedy EM, Bassit LC, Mueller H, Kornepati AVR, Bogerd HP, Nie T et al (2015) Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology 476:196–205
Joung JK, Sander JD (2013) TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol 14(1):49–55
Wooddell CI, Yuen MF, Chan HL, Gish RG, Locarnini SA, Chavez D et al (2017) RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci Trans Med 9(409)
Lam AM, Espiritu C, Vogel R, Ren S, Lau V, Kelly M et al (2019) Preclinical characterization of NVR 3-778, a first-in-class capsid assembly modulator against hepatitis B virus. Antimicrob Agents Chemother 63(1)
Klumpp K, Shimada T, Allweiss L, Volz T, Lutgehetmann M, Hartman G et al (2018) Efficacy of NVR 3-778, alone and in combination with pegylated interferon, vs entecavir in uPA/SCID mice with humanized livers and HBV infection. Gastroenterology 154(3):652–662. e8
Yuen MF, Gane EJ, Kim DJ, Weilert F, Yuen Chan HL, Lalezari J et al (2019) Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection. Gastroenterology
Zoulim F, Yogaratnam J, Vandenbossche JJ, Moscalu I, Streinu-Cercel A, Lenz O et al (2019) Safety, pharmacokinetics and antiviral activity of a novel hepatitis B virus capsid assembly modulator, JNJ-56136379, in Patients with Chronic Hepatitis B. APASL. Adv Ther 36(9):2450–2462
Zhang HZX, Chen H et al (2018) Safety, Pharmacokinetics and anti-viral efficacy of novel core protein allosteric modifier GLS4 in patients with chronic hepatitis B: interim results from a 48 weeks phase 2a Study. AASLD 2018 Abstract LB-13
Ma XL Lalezari J et al (2019) Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients. EASL 2019 Abs LBO-06. Hepatology 70(1):e130
Lampertico P (2014) Oral antiviral therapy for hepatitis B: the case of besifovir, a new kid on the block with a long way to go. Gut 63(6):869–870
Lai CL, Ahn SH, Lee KS, Um SH, Cho M, Yoon SK et al (2014) Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut 63(6):996–1004
Ahn SH, Kim W, Jung YK, Yang JM, Jang JY, Kweon YO et al (2019) Efficacy and safety of besifovir dipivoxil maleate compared with tenofovir disoproxil fumarate in treatment of chronic hepatitis B virus infection. Clin Gastroenterol Hepatol 17(9):1850–1859.e4
Feng S, Gao L, Han X, Hu T, Hu Y, Liu H et al (2018) Discovery of small molecule therapeutics for treatment of chronic HBV infection. ACS Infect Dis 4(3):257–277
Painter GR, Almond MR, Trost LC, Lampert BM, Neyts J, De Clercq E et al (2007) Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. Antimicrob Agents Chemother 51(10):3505–3509
Cai CW, Lomonosova E, Moran EA, Cheng X, Patel KB, Bailly F et al (2014) Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity. Antivir Res 108:48–55
Edwards TC, Lomonosova E, Patel JA, Li Q, Villa JA, Gupta AK et al (2017) Inhibition of hepatitis B virus replication by N-hydroxyisoquinolinediones and related polyoxygenated heterocycles. Antivir Res 143:205–217
Grant E, Joshi A, Ayithan N, Daffis S, Woo J, Lam T et al (2018) Pharmacodynamic response to oral administration of the selective toll-like receptor 8 agonist GS-9688 in healthy volunteers. Hepatology (Baltimore, MD) 68:270a–a
Lanford RE, Guerra B, Chavez D, Giavedoni L, Hodara VL, Brasky KM et al (2013) GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 144(7).:1508–1517, 17.e1–17.e10
Wenjin Z, Chuanhui P, Yunle W, Lateef SA, Shusen Z (2012) Longitudinal fluctuations in PD1 and PD-L1 expression in association with changes in anti-viral immune response in chronic hepatitis B. BMC Gastroenterol 12:109
El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389(10088):2492–2502
Boni C, Janssen HLA, Rossi M, Yoon SK, Vecchi A, Barili V et al (2019) Combined GS-4774 and tenofovir therapy can improve HBV-specific T-cell responses in patients with chronic hepatitis. Gastroenterology 157(1):227–241.e7
Lok AS, Pan CQ, Han SH, Trinh HN, Fessel WJ, Rodell T et al (2016) Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. J Hepatol 65(3):509–516
Martin P, Dubois C, Jacquier E, Dion S, Mancini-Bourgine M, Godon O et al (2015) TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice. Gut 64(12):1961–1971
Liang TJ, Block TM, McMahon BJ, Ghany MG, Urban S, Guo JT et al (2015) Present and future therapies of hepatitis B: from discovery to cure. Hepatology (Baltimore, MD) 62(6):1893–1908
Brahmania M, Feld J, Arif A, Janssen HL (2016) New therapeutic agents for chronic hepatitis B. Lancet Infect Dis 16(2):e10–e21
Acknowledgments
This work was supported by a grant from the National Natural Science Foundation of China (No.81772193).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Li, H. et al. (2020). Hepatitis B Virus Infection: Overview. In: Tang, H. (eds) Hepatitis B Virus Infection. Advances in Experimental Medicine and Biology, vol 1179. Springer, Singapore. https://doi.org/10.1007/978-981-13-9151-4_1
Download citation
DOI: https://doi.org/10.1007/978-981-13-9151-4_1
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-9150-7
Online ISBN: 978-981-13-9151-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)